 | • レポートコード：QYR2104Z1019 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、154ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥565,500 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥848,250 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,131,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、ブルトン型チロシンキナーゼ（BTK）阻害剤のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（不可逆阻害剤、可逆阻害剤）、用途別市場規模（慢性リンパ性白血病（cll）、濾胞性リンパ腫、マントル細胞リンパ腫、辺縁帯リンパ腫、小リンパ球性リンパ腫、ワルデンストレームマクログロブリン血症、その他の選択的B細胞悪性腫瘍、慢性移植片対宿主病、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・ブルトン型チロシンキナーゼ（BTK）阻害剤の市場動向 ・企業の競争状況、市場シェア ・ブルトン型チロシンキナーゼ（BTK）阻害剤の種類別市場規模（不可逆阻害剤、可逆阻害剤） ・ブルトン型チロシンキナーゼ（BTK）阻害剤の用途別市場規模（慢性リンパ性白血病（cll）、濾胞性リンパ腫、マントル細胞リンパ腫、辺縁帯リンパ腫、小リンパ球性リンパ腫、ワルデンストレームマクログロブリン血症、その他の選択的B細胞悪性腫瘍、慢性移植片対宿主病、その他） ・ブルトン型チロシンキナーゼ（BTK）阻害剤の北米市場規模2016-2027（アメリカ、カナダ） ・ブルトン型チロシンキナーゼ（BTK）阻害剤のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・ブルトン型チロシンキナーゼ（BTK）阻害剤のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ブルトン型チロシンキナーゼ（BTK）阻害剤の中南米市場規模2016-2027（メキシコ、ブラジル） ・ブルトン型チロシンキナーゼ（BTK）阻害剤の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Johnson & Johnson、AstraZeneca、Roche、Sunesis、Takeda、Bristol- Myers Squibb、Gilead Sciences、AbbVie、Biogen、INNOCARE、ACEA Biosciences、Acerta Pharma、Aptose Biosciences、ArQule、BeiGene、Carna Biosciences、Celgene Corporation、Eternity Bioscience、Hanmi Pharmaceutical、KBP Biosciences、Loxo Oncology、LSK BioPharma、Merck、Ono Pharmaceutical、Pharmacyclics、Principia Biopharma、Tolero、X-Rx、Zhejiang DTRM Biopharma） ・結論 |
Bruton’s tyrosine kinase (Btk), a member of the non-receptor tyrosine kinase Tec family, is a key signaling enzyme expressed in all hematopoietic cell types except T lymphocytes and natural killer cells.Btk plays a crucial role in stimulating B cell signaling pathways that connect the cell surface B cell receptor (BCR) to the downstream intracellular response.
Market Analysis and Insights: Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market
The global Bruton’s Tyrosine Kinase (BTK) Inhibitors market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bruton’s Tyrosine Kinase (BTK) Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bruton’s Tyrosine Kinase (BTK) Inhibitors market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bruton’s Tyrosine Kinase (BTK) Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bruton’s Tyrosine Kinase (BTK) Inhibitors market.
Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Scope and Market Size
Bruton’s Tyrosine Kinase (BTK) Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bruton’s Tyrosine Kinase (BTK) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Irreversible Inhibitor
Reversible Inhibitor
Segment by Application
Chronic Lymphocytic Leukemia (cll)
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Other Selective B Cell Malignancies
Chronic Graft-versus-host Disease
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Johnson & Johnson
AstraZeneca
Roche
Sunesis
Takeda
Bristol- Myers Squibb
Gilead Sciences
AbbVie
Biogen
INNOCARE
ACEA Biosciences
Acerta Pharma
Aptose Biosciences
ArQule
BeiGene
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Hanmi Pharmaceutical
KBP Biosciences
Loxo Oncology
LSK BioPharma
Merck
Ono Pharmaceutical
Pharmacyclics
Principia Biopharma
Tolero
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Irreversible Inhibitor
1.2.3 Reversible Inhibitor
1.3 Market by Application
1.3.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Chronic Lymphocytic Leukemia (cll)
1.3.3 Follicular Lymphoma
1.3.4 Mantle Cell Lymphoma
1.3.5 Marginal Zone Lymphoma
1.3.6 Small Lymphocytic Lymphoma
1.3.7 Waldenstrom Macroglobulinemia
1.3.8 Other Selective B Cell Malignancies
1.3.9 Chronic Graft-versus-host Disease
1.3.10 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Perspective (2016-2027)
2.2 Bruton’s Tyrosine Kinase (BTK) Inhibitors Growth Trends by Regions
2.2.1 Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Bruton’s Tyrosine Kinase (BTK) Inhibitors Historic Market Share by Regions (2016-2021)
2.2.3 Bruton’s Tyrosine Kinase (BTK) Inhibitors Forecasted Market Size by Regions (2022-2027)
2.3 Bruton’s Tyrosine Kinase (BTK) Inhibitors Industry Dynamic
2.3.1 Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Trends
2.3.2 Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Drivers
2.3.3 Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Challenges
2.3.4 Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bruton’s Tyrosine Kinase (BTK) Inhibitors Players by Revenue
3.1.1 Global Top Bruton’s Tyrosine Kinase (BTK) Inhibitors Players by Revenue (2016-2021)
3.1.2 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Players (2016-2021)
3.2 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue
3.4 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Concentration Ratio
3.4.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue in 2020
3.5 Bruton’s Tyrosine Kinase (BTK) Inhibitors Key Players Head office and Area Served
3.6 Key Players Bruton’s Tyrosine Kinase (BTK) Inhibitors Product Solution and Service
3.7 Date of Enter into Bruton’s Tyrosine Kinase (BTK) Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bruton’s Tyrosine Kinase (BTK) Inhibitors Breakdown Data by Type
4.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Historic Market Size by Type (2016-2021)
4.2 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Forecasted Market Size by Type (2022-2027)
5 Bruton’s Tyrosine Kinase (BTK) Inhibitors Breakdown Data by Application
5.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Historic Market Size by Application (2016-2021)
5.2 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size (2016-2027)
6.2 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type
6.2.1 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021)
6.2.2 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027)
6.2.3 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2027)
6.3 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application
6.3.1 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021)
6.3.2 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027)
6.3.3 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2027)
6.4 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country
6.4.1 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2016-2021)
6.4.2 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size (2016-2027)
7.2 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type
7.2.1 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021)
7.2.2 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027)
7.2.3 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2027)
7.3 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application
7.3.1 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021)
7.3.2 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027)
7.3.3 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2027)
7.4 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country
7.4.1 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2016-2021)
7.4.2 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size (2016-2027)
8.2 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type
8.2.1 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2027)
8.3 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application
8.3.1 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2027)
8.4 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Region
8.4.1 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size (2016-2027)
9.2 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type
9.2.1 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021)
9.2.2 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027)
9.2.3 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2027)
9.3 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application
9.3.1 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021)
9.3.2 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027)
9.3.3 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2027)
9.4 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country
9.4.1 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2016-2021)
9.4.2 Latin America Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size (2016-2027)
10.2 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type
10.2.1 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2027)
10.3 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application
10.3.1 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2027)
10.4 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country
10.4.1 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Details
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.1.4 Johnson & Johnson Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.1.5 Johnson & Johnson Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.2.4 AstraZeneca Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.2.5 AstraZeneca Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.3.4 Roche Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Sunesis
11.4.1 Sunesis Company Details
11.4.2 Sunesis Business Overview
11.4.3 Sunesis Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.4.4 Sunesis Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.4.5 Sunesis Recent Development
11.5 Takeda
11.5.1 Takeda Company Details
11.5.2 Takeda Business Overview
11.5.3 Takeda Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.5.4 Takeda Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.5.5 Takeda Recent Development
11.6 Bristol- Myers Squibb
11.6.1 Bristol- Myers Squibb Company Details
11.6.2 Bristol- Myers Squibb Business Overview
11.6.3 Bristol- Myers Squibb Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.6.4 Bristol- Myers Squibb Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.6.5 Bristol- Myers Squibb Recent Development
11.7 Gilead Sciences
11.7.1 Gilead Sciences Company Details
11.7.2 Gilead Sciences Business Overview
11.7.3 Gilead Sciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.7.4 Gilead Sciences Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.7.5 Gilead Sciences Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Details
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.8.4 AbbVie Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.8.5 AbbVie Recent Development
11.9 Biogen
11.9.1 Biogen Company Details
11.9.2 Biogen Business Overview
11.9.3 Biogen Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.9.4 Biogen Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.9.5 Biogen Recent Development
11.10 INNOCARE
11.10.1 INNOCARE Company Details
11.10.2 INNOCARE Business Overview
11.10.3 INNOCARE Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.10.4 INNOCARE Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.10.5 INNOCARE Recent Development
11.11 ACEA Biosciences
11.11.1 ACEA Biosciences Company Details
11.11.2 ACEA Biosciences Business Overview
11.11.3 ACEA Biosciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.11.4 ACEA Biosciences Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.11.5 ACEA Biosciences Recent Development
11.12 Acerta Pharma
11.12.1 Acerta Pharma Company Details
11.12.2 Acerta Pharma Business Overview
11.12.3 Acerta Pharma Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.12.4 Acerta Pharma Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.12.5 Acerta Pharma Recent Development
11.13 Aptose Biosciences
11.13.1 Aptose Biosciences Company Details
11.13.2 Aptose Biosciences Business Overview
11.13.3 Aptose Biosciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.13.4 Aptose Biosciences Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.13.5 Aptose Biosciences Recent Development
11.14 ArQule
11.14.1 ArQule Company Details
11.14.2 ArQule Business Overview
11.14.3 ArQule Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.14.4 ArQule Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.14.5 ArQule Recent Development
11.15 BeiGene
11.15.1 BeiGene Company Details
11.15.2 BeiGene Business Overview
11.15.3 BeiGene Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.15.4 BeiGene Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.15.5 BeiGene Recent Development
11.16 Carna Biosciences
11.16.1 Carna Biosciences Company Details
11.16.2 Carna Biosciences Business Overview
11.16.3 Carna Biosciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.16.4 Carna Biosciences Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.16.5 Carna Biosciences Recent Development
11.17 Celgene Corporation
11.17.1 Celgene Corporation Company Details
11.17.2 Celgene Corporation Business Overview
11.17.3 Celgene Corporation Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.17.4 Celgene Corporation Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.17.5 Celgene Corporation Recent Development
11.18 Eternity Bioscience
11.18.1 Eternity Bioscience Company Details
11.18.2 Eternity Bioscience Business Overview
11.18.3 Eternity Bioscience Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.18.4 Eternity Bioscience Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.18.5 Eternity Bioscience Recent Development
11.18 Hanmi Pharmaceutical
11.25.1 Hanmi Pharmaceutical Company Details
11.25.2 Hanmi Pharmaceutical Business Overview
11.25.3 Hanmi Pharmaceutical Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.25.4 Hanmi Pharmaceutical Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.25.5 Hanmi Pharmaceutical Recent Development
11.20 KBP Biosciences
11.20.1 KBP Biosciences Company Details
11.20.2 KBP Biosciences Business Overview
11.20.3 KBP Biosciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.20.4 KBP Biosciences Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.20.5 KBP Biosciences Recent Development
11.21 Loxo Oncology
11.21.1 Loxo Oncology Company Details
11.21.2 Loxo Oncology Business Overview
11.21.3 Loxo Oncology Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.21.4 Loxo Oncology Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.21.5 Loxo Oncology Recent Development
11.22 LSK BioPharma
11.22.1 LSK BioPharma Company Details
11.22.2 LSK BioPharma Business Overview
11.22.3 LSK BioPharma Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.22.4 LSK BioPharma Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.22.5 LSK BioPharma Recent Development
11.23 Merck
11.23.1 Merck Company Details
11.23.2 Merck Business Overview
11.23.3 Merck Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.23.4 Merck Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.23.5 Merck Recent Development
11.24 Ono Pharmaceutical
11.24.1 Ono Pharmaceutical Company Details
11.24.2 Ono Pharmaceutical Business Overview
11.24.3 Ono Pharmaceutical Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.24.4 Ono Pharmaceutical Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.24.5 Ono Pharmaceutical Recent Development
11.25 Pharmacyclics
11.25.1 Pharmacyclics Company Details
11.25.2 Pharmacyclics Business Overview
11.25.3 Pharmacyclics Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.25.4 Pharmacyclics Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.25.5 Pharmacyclics Recent Development
11.26 Principia Biopharma
11.26.1 Principia Biopharma Company Details
11.26.2 Principia Biopharma Business Overview
11.26.3 Principia Biopharma Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.26.4 Principia Biopharma Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.26.5 Principia Biopharma Recent Development
11.27 Tolero
11.27.1 Tolero Company Details
11.27.2 Tolero Business Overview
11.27.3 Tolero Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.27.4 Tolero Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.27.5 Tolero Recent Development
11.28 X-Rx
11.28.1 X-Rx Company Details
11.28.2 X-Rx Business Overview
11.28.3 X-Rx Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.28.4 X-Rx Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.28.5 X-Rx Recent Development
11.29 Zhejiang DTRM Biopharma
11.29.1 Zhejiang DTRM Biopharma Company Details
11.29.2 Zhejiang DTRM Biopharma Business Overview
11.29.3 Zhejiang DTRM Biopharma Bruton’s Tyrosine Kinase (BTK) Inhibitors Introduction
11.29.4 Zhejiang DTRM Biopharma Revenue in Bruton’s Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
11.29.5 Zhejiang DTRM Biopharma Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Irreversible Inhibitor
Table 3. Key Players of Reversible Inhibitor
Table 4. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Regions (2016-2021)
Table 8. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Regions (2022-2027)
Table 10. Bruton's Tyrosine Kinase (BTK) Inhibitors Market Trends
Table 11. Bruton's Tyrosine Kinase (BTK) Inhibitors Market Drivers
Table 12. Bruton's Tyrosine Kinase (BTK) Inhibitors Market Challenges
Table 13. Bruton's Tyrosine Kinase (BTK) Inhibitors Market Restraints
Table 14. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Players (2016-2021)
Table 16. Global Top Bruton's Tyrosine Kinase (BTK) Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors as of 2020)
Table 17. Ranking of Global Top Bruton's Tyrosine Kinase (BTK) Inhibitors Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Bruton's Tyrosine Kinase (BTK) Inhibitors Product Solution and Service
Table 21. Date of Enter into Bruton's Tyrosine Kinase (BTK) Inhibitors Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Type (2016-2021)
Table 25. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Application (2016-2021)
Table 29. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size by Country (2022-2027) & (US$ Million)
Table 61. Johnson & Johnson Company Details
Table 62. Johnson & Johnson Business Overview
Table 63. Johnson & Johnson Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 64. Johnson & Johnson Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 65. Johnson & Johnson Recent Development
Table 66. AstraZeneca Company Details
Table 67. AstraZeneca Business Overview
Table 68. AstraZeneca Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 69. AstraZeneca Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 70. AstraZeneca Recent Development
Table 71. Roche Company Details
Table 72. Roche Business Overview
Table 73. Roche Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 74. Roche Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 75. Roche Recent Development
Table 76. Sunesis Company Details
Table 77. Sunesis Business Overview
Table 78. Sunesis Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 79. Sunesis Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 80. Sunesis Recent Development
Table 81. Takeda Company Details
Table 82. Takeda Business Overview
Table 83. Takeda Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 84. Takeda Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 85. Takeda Recent Development
Table 86. Bristol- Myers Squibb Company Details
Table 87. Bristol- Myers Squibb Business Overview
Table 88. Bristol- Myers Squibb Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 89. Bristol- Myers Squibb Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 90. Bristol- Myers Squibb Recent Development
Table 91. Gilead Sciences Company Details
Table 92. Gilead Sciences Business Overview
Table 93. Gilead Sciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 94. Gilead Sciences Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 95. Gilead Sciences Recent Development
Table 96. AbbVie Company Details
Table 97. AbbVie Business Overview
Table 98. AbbVie Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 99. AbbVie Recent Development
Table 100. Biogen Company Details
Table 101. Biogen Business Overview
Table 102. Biogen Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 103. Biogen Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 104. Biogen Recent Development
Table 105. INNOCARE Company Details
Table 106. INNOCARE Business Overview
Table 107. INNOCARE Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 108. INNOCARE Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 109. INNOCARE Recent Development
Table 110. ACEA Biosciences Company Details
Table 111. ACEA Biosciences Business Overview
Table 112. ACEA Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 113. ACEA Biosciences Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 114. ACEA Biosciences Recent Development
Table 115. Acerta Pharma Company Details
Table 116. Acerta Pharma Business Overview
Table 117. Acerta Pharma Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 118. Acerta Pharma Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 119. Acerta Pharma Recent Development
Table 120. Aptose Biosciences Company Details
Table 121. Aptose Biosciences Business Overview
Table 122. Aptose Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 123. Aptose Biosciences Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 124. Aptose Biosciences Recent Development
Table 125. ArQule Company Details
Table 126. ArQule Business Overview
Table 127. ArQule Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 128. ArQule Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 129. ArQule Recent Development
Table 130. BeiGene Company Details
Table 131. BeiGene Business Overview
Table 132. BeiGene Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 133. BeiGene Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 134. BeiGene Recent Development
Table 135. Carna Biosciences Company Details
Table 136. Carna Biosciences Business Overview
Table 137. Carna Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 138. Carna Biosciences Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 139. Carna Biosciences Recent Development
Table 140. Celgene Corporation Company Details
Table 141. Celgene Corporation Business Overview
Table 142. Celgene Corporation Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 143. Celgene Corporation Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 144. Celgene Corporation Recent Development
Table 145. Eternity Bioscience Company Details
Table 146. Eternity Bioscience Business Overview
Table 147. Eternity Bioscience Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 148. Eternity Bioscience Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 149. Eternity Bioscience Recent Development
Table 150. Hanmi Pharmaceutical Company Details
Table 151. Hanmi Pharmaceutical Business Overview
Table 152. Hanmi Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 153. Hanmi Pharmaceutical Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 154. Hanmi Pharmaceutical Recent Development
Table 155. KBP Biosciences Company Details
Table 156. KBP Biosciences Business Overview
Table 157. KBP Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 158. KBP Biosciences Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 159. KBP Biosciences Recent Development
Table 160. Loxo Oncology Company Details
Table 161. Loxo Oncology Business Overview
Table 162. Loxo Oncology Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 163. Loxo Oncology Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 164. Loxo Oncology Recent Development
Table 165. LSK BioPharma Company Details
Table 166. LSK BioPharma Business Overview
Table 167. LSK BioPharma Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 168. LSK BioPharma Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 169. LSK BioPharma Recent Development
Table 170. Merck Company Details
Table 171. Merck Business Overview
Table 172. Merck Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 173. Merck Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 174. Merck Recent Development
Table 175. Ono Pharmaceutical Company Details
Table 176. Ono Pharmaceutical Business Overview
Table 177. Ono Pharmaceutical Bruton's Tyrosine Kinase (BTK) InhibitorsProduct
Table 178. Ono Pharmaceutical Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 179. Ono Pharmaceutical Recent Development
Table 180. Pharmacyclics Company Details
Table 181. Pharmacyclics Business Overview
Table 182. Pharmacyclics Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 183. Pharmacyclics Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 184. Pharmacyclics Recent Development
Table 185. Principia Biopharma Company Details
Table 186. Principia Biopharma Business Overview
Table 187. Principia Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 188. Principia Biopharma Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 189. Principia Biopharma Recent Development
Table 190. Tolero Company Details
Table 191. Tolero Business Overview
Table 192. Tolero Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 193. Tolero Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 194. Tolero Recent Development
Table 195. X-Rx Company Details
Table 196. X-Rx Business Overview
Table 197. X-Rx Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 198. X-Rx Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 199. X-Rx Recent Development
Table 200. Zhejiang DTRM Biopharma Company Details
Table 201. Zhejiang DTRM Biopharma Business Overview
Table 202. Zhejiang DTRM Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Product
Table 203. Zhejiang DTRM Biopharma Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021) & (US$ Million)
Table 204. Zhejiang DTRM Biopharma Recent Development
Table 205. Research Programs/Design for This Report
Table 206. Key Data Information from Secondary Sources
Table 207. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Type: 2020 VS 2027
Figure 2. Irreversible Inhibitor Features
Figure 3. Reversible Inhibitor Features
Figure 4. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Application: 2020 VS 2027
Figure 5. Chronic Lymphocytic Leukemia (cll) Case Studies
Figure 6. Follicular Lymphoma Case Studies
Figure 7. Mantle Cell Lymphoma Case Studies
Figure 8. Marginal Zone Lymphoma Case Studies
Figure 9. Small Lymphocytic Lymphoma Case Studies
Figure 10. Waldenstrom Macroglobulinemia Case Studies
Figure 11. Other Selective B Cell Malignancies Case Studies
Figure 12. Chronic Graft-versus-host Disease Case Studies
Figure 13. Other Case Studies
Figure 14. Bruton's Tyrosine Kinase (BTK) Inhibitors Report Years Considered
Figure 15. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Regions: 2020 VS 2027
Figure 18. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Regions (2022-2027)
Figure 19. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Players in 2020
Figure 20. Global Top Bruton's Tyrosine Kinase (BTK) Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bruton's Tyrosine Kinase (BTK) Inhibitors as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue in 2020
Figure 22. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Type (2016-2021)
Figure 23. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Type (2022-2027)
Figure 24. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Type (2016-2027)
Figure 26. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Application (2016-2027)
Figure 27. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Country (2016-2027)
Figure 28. United States Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Type (2016-2027)
Figure 32. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Application (2016-2027)
Figure 33. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Country (2016-2027)
Figure 34. Germany Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Region (2016-2027)
Figure 44. China Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Type (2016-2027)
Figure 52. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Application (2016-2027)
Figure 53. Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Country (2016-2027)
Figure 54. Mexico Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share by Country (2016-2027)
Figure 60. Turkey Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Johnson & Johnson Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 64. AstraZeneca Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 65. Roche Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 66. Sunesis Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 67. Takeda Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 68. Bristol- Myers Squibb Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 69. Gilead Sciences Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 70. AbbVie Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 71. Biogen Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 72. INNOCARE Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 73. ACEA Biosciences Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 74. Acerta Pharma Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 75. Aptose Biosciences Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 76. ArQule Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 77. BeiGene Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 78. Carna Biosciences Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 79. Celgene Corporation Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 80. Eternity Bioscience Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 81. Hanmi Pharmaceutical Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 82. KBP Biosciences Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 83. Loxo Oncology Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 84. LSK BioPharma Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 85. Merck Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 86. Ono Pharmaceutical Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 87. Pharmacyclics Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 88. Principia Biopharma Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 89. Tolero Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 90. X-Rx Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 91. Zhejiang DTRM Biopharma Revenue Growth Rate in Bruton's Tyrosine Kinase (BTK) Inhibitors Business (2016-2021)
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
世界のサイクリン依存性キナーゼ阻害剤市場規模・現状・予測（2021年-2027年） Cyclin-dependent kinase inhibitor function as tumor suppressor proteins by inhibiting the enzyme cyclin-dependent kinase. The enzyme cyclin-dependent kinase controls cell cycle progression, transcription, mRNA processing, and differentiation. Cyclin-dependent kinase inhibitor arrest cell cycle at th…- 世界のマントル細胞リンパ腫治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Mantle Cell Lymphoma Treatment Market The global Mantle Cell Lymphoma Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data int…
- 世界の濾胞性リンパ腫治療薬市場規模・現状・予測（2021年-2027年） Follicular lymphoma is a type of blood cancer. It is the most common of the indolent (slow-growing) non-Hodgkin's lymphomas, and the second-most-common form of non-Hodgkin's lymphomas overall. It is defined as a lymphoma of follicle center B-cells (centrocytes and centroblasts), which has at least a…
- 世界の濾胞性リンパ腫治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Follicular Lymphoma Treatment Market The global Follicular Lymphoma Treatment market size is projected to reach US$ 2526.8 million by 2026, from US$ 1620.1 million in 2019, at a CAGR of 6.5% during 2021-2026. With industry-standard accuracy in analysis and high d…
- 世界のリンパ腫治療市場規模・現状・予測（2021年-2027年） Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the body. When you have lymphoma, lymphocytes change and grow out of control Market Analysis and Insights: Global L…